Sign Up Today and Learn More About Adaptive Biotechnologies Stock
Invest in or calculate the value of your shares in Adaptive Biotechnologies or other pre-IPO companies through EquityZen's platform.
Adaptive Biotechnologies Stock
DNA sequencing for cancer therapy & research
About Adaptive Biotechnologies Stock
Founded
2009
Headquarters
Seattle, WA, US
Total Funding
579M
Industries
Content and Publishing, Messaging and Telecommunications, Advertising
Adaptive Biotechnologies aims to help scientists look at the immune system in a new way, with a combination of DNA sequencing and high-powered computation, to analyze the DNA sequences that make up the immune system. Unlike other cell types, which operate on a fixed set of code from the human genome, immune system cells rearrange their DNA constantly in response to shifting threats in the environment. Sometimes the immune system malfunctions and begins attacking healthy tissues (i.e., autoimmune diseases) or certain immune system cells start proliferating out of control (i.e., cancer).
By digging into the immune cell sequences, Adaptive is aiming to create a map of human immune system responses to threats. Armed with this information, Adaptive seeks to develop blood tests that alert doctors when people are fighting specific diseases. Eventually, Adaptive wants to create a universal blood test that detects any disease a body might be fighting. Although such an all-encompassing test may be 10 years away, intermediate tests will come much sooner, according to CEO Chad Robins.
Adaptive was founded in 2009 by Chad Robins, Christopher Carlson, and Harlan Robins and is based in Seattle, Washington. The company has raised capital from investors such as Microsoft, Matrix Capital Management, Tiger Management and Viking Global Investors.
Source: Seattle Times; Crunchbase; Forbes
Overview of Adaptive Biotechnologies:
Source: WBBA TV
Adaptive Biotechnologies Press Mentions
Stay in the know about the latest news on Adaptive Biotechnologies
3 leadership lessons from Adaptive Biotechnologies CEO Chad Robins
geekwire • Mar 02, 2019
Global Liquid Biopsy Products Market Size 2018 – 23: Pathway Genomics, Guardant Health, Angle plc and Adaptive ...
Real Fact 24 • Dec 05, 2018
Adaptive Biotechnologies and Collaborators to Present 28 Studies at ASH 2018 that Support the Use of the clonoSEQ
Business Wire (press release) • Nov 30, 2018
Adaptive Biotechnologies, U of Florida, Kings College London Collaborate on Diabetes Study
GenomeWeb • Nov 14, 2018
How Microsoft and Adaptive Biotech became 'a single team' to build groundbreaking AI diagnostic
GeekWire • Oct 09, 2018
Investors in Adaptive Biotechnologies
Discover investors in Adaptive Biotechnologies stock and explore their portfolio companies
Adaptive Biotechnologies Management
Leadership team at Adaptive Biotechnologies
Co-Founder and CEO
Chad Robins
Co-Founder and Head of Innovation
Harlan Robins
Join now and verify your accreditation status to gain access to:
- Adaptive Biotechnologies Current Valuation
- Adaptive Biotechnologies Stock Price
- Adaptive Biotechnologies Management
- Available deals in Adaptive Biotechnologies and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Adaptive Biotechnologies Cap Table and Funding History by Share Class and Liquidity Preferences
- Adaptive Biotechnologies Revenue and Financials
- Adaptive Biotechnologies Highlights
- Adaptive Biotechnologies Business Model
- Adaptive Biotechnologies Risk Factors
- Adaptive Biotechnologies Research Report from SACRA Research
Trading Adaptive Biotechnologies Stock
How to invest in Adaptive Biotechnologies stock?
Accredited investors can buy pre-IPO stock in companies like Adaptive Biotechnologies through EquityZen funds. These investments are made available by existing Adaptive Biotechnologies shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Adaptive Biotechnologies stock?
Shareholders can sell their Adaptive Biotechnologies stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."